Properties of isonucleotide-incorporated oligodeoxynucleotides and inhibition of the expression of spike protein of SARS-CoV.
Identifieur interne : 001170 ( Ncbi/Merge ); précédent : 001169; suivant : 001171Properties of isonucleotide-incorporated oligodeoxynucleotides and inhibition of the expression of spike protein of SARS-CoV.
Auteurs : Zhanli Wang [République populaire de Chine] ; Jifeng Shi ; Hongwei Jin ; Liangren Zhang ; Jingfeng Lu ; Lihe ZhangSource :
- Bioconjugate chemistry [ 1043-1802 ]
Descripteurs français
- KwdFr :
- Conformation d'acide nucléique, Dichroïsme circulaire, Dénaturation d'acide nucléique, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (métabolisme), Hydrolyse (), Oligoribonucléotides (), Oligoribonucléotides (métabolisme), Oligoribonucléotides (pharmacologie), Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (métabolisme), Ribonuclease H (métabolisme), Régulation de l'expression des gènes viraux (), Régulation négative (génétique), Structure moléculaire, Température de transition, Virus du SRAS (), Virus du SRAS (génétique), Virus du SRAS (métabolisme).
- MESH :
- génétique : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Régulation négative, Virus du SRAS.
- métabolisme : Glycoprotéines membranaires, Oligoribonucléotides, Protéines de l'enveloppe virale, Ribonuclease H, Virus du SRAS.
- pharmacologie : Oligoribonucléotides.
- Conformation d'acide nucléique, Dichroïsme circulaire, Dénaturation d'acide nucléique, Glycoprotéine de spicule des coronavirus, Hydrolyse, Oligoribonucléotides, Régulation de l'expression des gènes viraux, Structure moléculaire, Température de transition, Virus du SRAS.
English descriptors
- KwdEn :
- Circular Dichroism, Down-Regulation (genetics), Gene Expression Regulation, Viral (drug effects), Hydrolysis (drug effects), Membrane Glycoproteins (genetics), Membrane Glycoproteins (metabolism), Molecular Structure, Nucleic Acid Conformation, Nucleic Acid Denaturation, Oligoribonucleotides (chemistry), Oligoribonucleotides (metabolism), Oligoribonucleotides (pharmacology), Ribonuclease H (metabolism), SARS Virus (drug effects), SARS Virus (genetics), SARS Virus (metabolism), Spike Glycoprotein, Coronavirus, Transition Temperature, Viral Envelope Proteins (genetics), Viral Envelope Proteins (metabolism).
- MESH :
- chemical , chemistry : Oligoribonucleotides.
- chemical , genetics : Membrane Glycoproteins, Viral Envelope Proteins.
- drug effects : Gene Expression Regulation, Viral, Hydrolysis, SARS Virus.
- genetics : Down-Regulation, SARS Virus.
- chemical , metabolism : Membrane Glycoproteins, Oligoribonucleotides, Ribonuclease H, SARS Virus, Viral Envelope Proteins.
- chemical , pharmacology : Oligoribonucleotides.
- Circular Dichroism, Molecular Structure, Nucleic Acid Conformation, Nucleic Acid Denaturation, Spike Glycoprotein, Coronavirus, Transition Temperature.
Abstract
Antisense oligonucleotides are recognized to be very efficient tools for the inhibition of gene expression in a sequence specific way. For the discovery of a novel efficient way to modify oligonucleotides, a series of single isonucleotide-incorporated antisense oligodeoxynucleotides have been synthesized, in which an isonucleotide was introduced at different positions of the sequences. The binding behaviors of modified oligodeoxynucleotides to the complementary sequence were studied by UV, CD, and molecular dynamics simulation. The results showed that although the incorporated isonucleotides at certain positions of the sequence interfere with the binding ability to a different extent, B-form duplexes were maintained and the binding abilities of the 3'-end-modified duplexes were better than the corresponding mismatched duplexes. The digestion of modified oligodeoxynucleotides by snake venom phosphodiesterase showed that an isonucleotide strongly antagonizes hydrolysis. The DNA/RNA hybrid formed by a modified oligodeoxynucleotide and its target RNA could activate RNase H. The 3'-end-modified antisense oligodeoxynucelotides inhibited S-glycoprotein expression of SARS-CoV at the mRNA levels in insect Sf9 cells. This study indicated the possibility of designing a novel and effective antisense oligodeoxynucleotide by incorporating an isonucleotide at the 3'-end of the sequence.
DOI: 10.1021/bc049769h
PubMed: 16173783
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002533
- to stream PubMed, to step Curation: 002533
- to stream PubMed, to step Checkpoint: 003520
Links to Exploration step
pubmed:16173783Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Properties of isonucleotide-incorporated oligodeoxynucleotides and inhibition of the expression of spike protein of SARS-CoV.</title>
<author><name sortKey="Wang, Zhanli" sort="Wang, Zhanli" uniqKey="Wang Z" first="Zhanli" last="Wang">Zhanli Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>National Research Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100083, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>National Research Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100083</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
<orgName type="university">Université de Pékin</orgName>
<placeName><settlement type="city">Pékin</settlement>
<region type="capitale">Pékin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shi, Jifeng" sort="Shi, Jifeng" uniqKey="Shi J" first="Jifeng" last="Shi">Jifeng Shi</name>
</author>
<author><name sortKey="Jin, Hongwei" sort="Jin, Hongwei" uniqKey="Jin H" first="Hongwei" last="Jin">Hongwei Jin</name>
</author>
<author><name sortKey="Zhang, Liangren" sort="Zhang, Liangren" uniqKey="Zhang L" first="Liangren" last="Zhang">Liangren Zhang</name>
</author>
<author><name sortKey="Lu, Jingfeng" sort="Lu, Jingfeng" uniqKey="Lu J" first="Jingfeng" last="Lu">Jingfeng Lu</name>
</author>
<author><name sortKey="Zhang, Lihe" sort="Zhang, Lihe" uniqKey="Zhang L" first="Lihe" last="Zhang">Lihe Zhang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2005 Sep-Oct</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:16173783</idno>
<idno type="pmid">16173783</idno>
<idno type="doi">10.1021/bc049769h</idno>
<idno type="wicri:Area/PubMed/Corpus">002533</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002533</idno>
<idno type="wicri:Area/PubMed/Curation">002533</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002533</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003520</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003520</idno>
<idno type="wicri:Area/Ncbi/Merge">001170</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Properties of isonucleotide-incorporated oligodeoxynucleotides and inhibition of the expression of spike protein of SARS-CoV.</title>
<author><name sortKey="Wang, Zhanli" sort="Wang, Zhanli" uniqKey="Wang Z" first="Zhanli" last="Wang">Zhanli Wang</name>
<affiliation wicri:level="4"><nlm:affiliation>National Research Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100083, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>National Research Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100083</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
<orgName type="university">Université de Pékin</orgName>
<placeName><settlement type="city">Pékin</settlement>
<region type="capitale">Pékin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shi, Jifeng" sort="Shi, Jifeng" uniqKey="Shi J" first="Jifeng" last="Shi">Jifeng Shi</name>
</author>
<author><name sortKey="Jin, Hongwei" sort="Jin, Hongwei" uniqKey="Jin H" first="Hongwei" last="Jin">Hongwei Jin</name>
</author>
<author><name sortKey="Zhang, Liangren" sort="Zhang, Liangren" uniqKey="Zhang L" first="Liangren" last="Zhang">Liangren Zhang</name>
</author>
<author><name sortKey="Lu, Jingfeng" sort="Lu, Jingfeng" uniqKey="Lu J" first="Jingfeng" last="Lu">Jingfeng Lu</name>
</author>
<author><name sortKey="Zhang, Lihe" sort="Zhang, Lihe" uniqKey="Zhang L" first="Lihe" last="Zhang">Lihe Zhang</name>
</author>
</analytic>
<series><title level="j">Bioconjugate chemistry</title>
<idno type="ISSN">1043-1802</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Circular Dichroism</term>
<term>Down-Regulation (genetics)</term>
<term>Gene Expression Regulation, Viral (drug effects)</term>
<term>Hydrolysis (drug effects)</term>
<term>Membrane Glycoproteins (genetics)</term>
<term>Membrane Glycoproteins (metabolism)</term>
<term>Molecular Structure</term>
<term>Nucleic Acid Conformation</term>
<term>Nucleic Acid Denaturation</term>
<term>Oligoribonucleotides (chemistry)</term>
<term>Oligoribonucleotides (metabolism)</term>
<term>Oligoribonucleotides (pharmacology)</term>
<term>Ribonuclease H (metabolism)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (metabolism)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Transition Temperature</term>
<term>Viral Envelope Proteins (genetics)</term>
<term>Viral Envelope Proteins (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Conformation d'acide nucléique</term>
<term>Dichroïsme circulaire</term>
<term>Dénaturation d'acide nucléique</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (génétique)</term>
<term>Glycoprotéines membranaires (métabolisme)</term>
<term>Hydrolyse ()</term>
<term>Oligoribonucléotides ()</term>
<term>Oligoribonucléotides (métabolisme)</term>
<term>Oligoribonucléotides (pharmacologie)</term>
<term>Protéines de l'enveloppe virale (génétique)</term>
<term>Protéines de l'enveloppe virale (métabolisme)</term>
<term>Ribonuclease H (métabolisme)</term>
<term>Régulation de l'expression des gènes viraux ()</term>
<term>Régulation négative (génétique)</term>
<term>Structure moléculaire</term>
<term>Température de transition</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (métabolisme)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Oligoribonucleotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gene Expression Regulation, Viral</term>
<term>Hydrolysis</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Down-Regulation</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Régulation négative</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Oligoribonucleotides</term>
<term>Ribonuclease H</term>
<term>SARS Virus</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Oligoribonucléotides</term>
<term>Protéines de l'enveloppe virale</term>
<term>Ribonuclease H</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Oligoribonucléotides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Oligoribonucleotides</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Circular Dichroism</term>
<term>Molecular Structure</term>
<term>Nucleic Acid Conformation</term>
<term>Nucleic Acid Denaturation</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Transition Temperature</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Conformation d'acide nucléique</term>
<term>Dichroïsme circulaire</term>
<term>Dénaturation d'acide nucléique</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Hydrolyse</term>
<term>Oligoribonucléotides</term>
<term>Régulation de l'expression des gènes viraux</term>
<term>Structure moléculaire</term>
<term>Température de transition</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Antisense oligonucleotides are recognized to be very efficient tools for the inhibition of gene expression in a sequence specific way. For the discovery of a novel efficient way to modify oligonucleotides, a series of single isonucleotide-incorporated antisense oligodeoxynucleotides have been synthesized, in which an isonucleotide was introduced at different positions of the sequences. The binding behaviors of modified oligodeoxynucleotides to the complementary sequence were studied by UV, CD, and molecular dynamics simulation. The results showed that although the incorporated isonucleotides at certain positions of the sequence interfere with the binding ability to a different extent, B-form duplexes were maintained and the binding abilities of the 3'-end-modified duplexes were better than the corresponding mismatched duplexes. The digestion of modified oligodeoxynucleotides by snake venom phosphodiesterase showed that an isonucleotide strongly antagonizes hydrolysis. The DNA/RNA hybrid formed by a modified oligodeoxynucleotide and its target RNA could activate RNase H. The 3'-end-modified antisense oligodeoxynucelotides inhibited S-glycoprotein expression of SARS-CoV at the mRNA levels in insect Sf9 cells. This study indicated the possibility of designing a novel and effective antisense oligodeoxynucleotide by incorporating an isonucleotide at the 3'-end of the sequence.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16173783</PMID>
<DateCompleted><Year>2005</Year>
<Month>12</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1043-1802</ISSN>
<JournalIssue CitedMedium="Print"><Volume>16</Volume>
<Issue>5</Issue>
<PubDate><MedlineDate>2005 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Bioconjugate chemistry</Title>
<ISOAbbreviation>Bioconjug. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Properties of isonucleotide-incorporated oligodeoxynucleotides and inhibition of the expression of spike protein of SARS-CoV.</ArticleTitle>
<Pagination><MedlinePgn>1081-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Antisense oligonucleotides are recognized to be very efficient tools for the inhibition of gene expression in a sequence specific way. For the discovery of a novel efficient way to modify oligonucleotides, a series of single isonucleotide-incorporated antisense oligodeoxynucleotides have been synthesized, in which an isonucleotide was introduced at different positions of the sequences. The binding behaviors of modified oligodeoxynucleotides to the complementary sequence were studied by UV, CD, and molecular dynamics simulation. The results showed that although the incorporated isonucleotides at certain positions of the sequence interfere with the binding ability to a different extent, B-form duplexes were maintained and the binding abilities of the 3'-end-modified duplexes were better than the corresponding mismatched duplexes. The digestion of modified oligodeoxynucleotides by snake venom phosphodiesterase showed that an isonucleotide strongly antagonizes hydrolysis. The DNA/RNA hybrid formed by a modified oligodeoxynucleotide and its target RNA could activate RNase H. The 3'-end-modified antisense oligodeoxynucelotides inhibited S-glycoprotein expression of SARS-CoV at the mRNA levels in insect Sf9 cells. This study indicated the possibility of designing a novel and effective antisense oligodeoxynucleotide by incorporating an isonucleotide at the 3'-end of the sequence.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Zhanli</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>National Research Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100083, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shi</LastName>
<ForeName>Jifeng</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Hongwei</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Liangren</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Jingfeng</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Lihe</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Bioconjug Chem</MedlineTA>
<NlmUniqueID>9010319</NlmUniqueID>
<ISSNLinking>1043-1802</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009843">Oligoribonucleotides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.1.26.4</RegistryNumber>
<NameOfSubstance UI="D016914">Ribonuclease H</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015967" MajorTopicYN="N">Gene Expression Regulation, Viral</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009690" MajorTopicYN="N">Nucleic Acid Conformation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009691" MajorTopicYN="N">Nucleic Acid Denaturation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009843" MajorTopicYN="N">Oligoribonucleotides</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016914" MajorTopicYN="N">Ribonuclease H</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D044366" MajorTopicYN="N">Transition Temperature</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>9</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>12</Month>
<Day>24</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>9</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16173783</ArticleId>
<ArticleId IdType="doi">10.1021/bc049769h</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<region><li>Pékin</li>
</region>
<settlement><li>Pékin</li>
</settlement>
<orgName><li>Université de Pékin</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Jin, Hongwei" sort="Jin, Hongwei" uniqKey="Jin H" first="Hongwei" last="Jin">Hongwei Jin</name>
<name sortKey="Lu, Jingfeng" sort="Lu, Jingfeng" uniqKey="Lu J" first="Jingfeng" last="Lu">Jingfeng Lu</name>
<name sortKey="Shi, Jifeng" sort="Shi, Jifeng" uniqKey="Shi J" first="Jifeng" last="Shi">Jifeng Shi</name>
<name sortKey="Zhang, Liangren" sort="Zhang, Liangren" uniqKey="Zhang L" first="Liangren" last="Zhang">Liangren Zhang</name>
<name sortKey="Zhang, Lihe" sort="Zhang, Lihe" uniqKey="Zhang L" first="Lihe" last="Zhang">Lihe Zhang</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Wang, Zhanli" sort="Wang, Zhanli" uniqKey="Wang Z" first="Zhanli" last="Wang">Zhanli Wang</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001170 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001170 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:16173783 |texte= Properties of isonucleotide-incorporated oligodeoxynucleotides and inhibition of the expression of spike protein of SARS-CoV. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16173783" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |